#Scinai Immunotherapeutics #Israel #Jerusalem #Biopharmaceutical #CDMO

Scinai Immunotherapeutics Secures $4 Million Financing

In a significant move designed to enhance its operational capacity and accelerate its growth trajectory, Scinai Immunotherapeutics Ltd. has recently announced the completion of a $4 million financing arrangement. As a prominent player in the biopharmaceutical industry, Scinai is poised to utilize these funds to further develop its Contract Development and Manufacturing Organization (CDMO) platform, alongside advancing its pipeline in immunotherapy therapeutics.

Details of the Financing Arrangement

The financing was secured through a Securities Purchase Agreement with a reputable institutional investor in the life sciences sector. The deal involves the purchase and sale of approximately 2,458,334 American Depositary Shares (ADSs), which represent ordinary shares of the company, and includes Series A-1 warrants enabling the purchase of an additional 3,687,501 ADSs at a specified exercise price. This agreement reflects confidence in Scinai's growth potential amidst a competitive market landscape.

Additionally, Scinai has structured the agreement to include a warrant inducement component, allowing the immediate cash exercise of existing warrants issued earlier in the year. This strategy is aligned with the company's objective to ensure liquidity and support its ongoing operational projects.

The gross proceeds from this private placement and inducement agreement are anticipated to be in the vicinity of $4 million, which will assist in fulfilling the company’s growth strategies. Notably, the closing of these transactions is tentatively scheduled for mid-October 2026, contingent upon customary closing conditions.

Strategic Goals and Utilization of Proceeds

Scinai plans to channel the net proceeds, along with its existing cash reserves, towards the expansion of its CDMO capabilities. This decision aims to enhance service offerings to biotechnology and pharmaceutical companies, positioning Scinai as a strategically important partner in the industry. Furthermore, the funding is expected to facilitate progress in customer programs while selectively investing in its immunotherapy pipeline, particularly its innovative NanoAb platform.

The NanoAb platform is recognized for its advanced therapeutic approaches, and collaboration agreements with esteemed institutions such as the Max Planck Society and University Medical Center Göttingen in Germany underscore its potential within the international research community.

Market Context and Future Outlook

As a biopharmaceutical organization, Scinai stands at the intersection of innovation and market demand. The financing initiative resonates with the overall trend of strategic funding in the life sciences sector, where companies are increasingly leveraging public and private capital to fuel R&D and operational growth. Furthermore, the company's commitment to transparency regarding the registration of the new securities under applicable regulations indicates a proactive approach in preparing for future scalability.

The biopharmaceutical landscape is characterized by rapid advancements and shifting regulatory frameworks, making strategic financial alignments crucial to long-term sustainability. With this financing round, Scinai Immunotherapeutics is well-positioned to navigate these challenges while capitalizing on emerging opportunities.

This announcement reaffirms Scinai's commitment to advancing healthcare solutions through innovative therapies and robust partnerships, potentially paving the way for further breakthroughs in immunotherapy treatments.

For more information, please visit Scinai’s official website.

About Scinai Immunotherapeutics

Founded with a vision to innovate in the fields of immunology and biopharmaceutical services, Scinai operates a growing CDMO along with an advanced therapeutic development platform. Headquartered in Jerusalem, the company is dedicated to providing high-quality development and manufacturing services to companies within the biotechnology and pharmaceutical sectors, ensuring the delivery of cutting-edge healthcare solutions to meet global needs.